Siam Cement Group (SCG) Ventures

SCG Ventures is the broader venture arm of Siam Cement Group, the Thai industrial conglomerate with major holdings in cement, chemicals, packaging, and an expanding strategic footprint in adjacent technology categories. Healthcare appears in the thesis through digital health, with stage focus on Series A and Series B and checks in the $1M to $5M range. AI is not a primary stated focus, which is consistent with the strategic-CVC profile. The right founder is a Southeast Asian or globally relevant healthcare operator whose product creates strategic value to SCG’s industrial portfolio, including occupational health for industrial workforces, supply chain or logistics health applications, building-environment health technologies, or B2B healthcare commerce that can leverage SCG’s distribution and operational infrastructure. The wrong founder is a consumer wellness brand without industrial relevance, a pure clinical telehealth play, or a deep biotech team needing scientific syndicate construction. Intro paths run through SCG corporate development and the SCG Ventures team directly, through Bangkok’s tight venture network including 500 TukTuks, InVent, Krungsri Finnovate, and Beacon, and through Singapore-based regional health funds such as Heritas Capital and Pavilion Capital. SCG’s own business-unit executives, particularly in chemicals and packaging which touch healthcare adjacencies, are also natural connectors. In the pitch, lead with the strategic angle: how does your healthcare business create incremental value for one of SCG’s operating businesses, whether through workforce health, environmental monitoring, packaging innovation for pharma, or distribution into industrial channels. Show traction with one or two anchor enterprise customers, ideally in Thailand or the wider ASEAN region, and a candid view of regulatory positioning under FDA Thailand and PDPA. Caveats are the standard CVC ones, plus the specific reality that SCG is a publicly listed conglomerate with corporate governance and ESG dynamics that can slow deal cadence relative to financial VC. Founders who can articulate a clean strategic value to SCG and operate with patience get a powerful industrial partner; founders chasing it for branded validation alone tend to find the strategic fit harder to manufacture than they expect.